drugset / Trial / NCT04435782

A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging

NCT04435782

Phase 4 Terminated 9 enrolled Actelion
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the effects of selexipag on right ventricular (RV) function in participants with Pulmonary arterial hypertension (PAH).

Timeline

Start
2021-07-07
Primary completion
2023-07-28
Completion
2023-07-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Selexipag Small molecule 200 ug